Phase III CMC Data Requirements Should Be Shifted to NDA, PhRMA Says
Executive Summary
FDA's recommendations for chemistry, manufacturing and controls content and format in Phase III INDs are more appropriate for NDA submissions, the Pharmaceutical Research & Manufacturers of America asserted in comments on FDA's Phase II and Phase III IND draft guidance.